A carregar...

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML

The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic opti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Mol Sci
Main Authors: Carofiglio, Francesca, Lopalco, Antonio, Lopedota, Angela, Cutrignelli, Annalisa, Nicolotti, Orazio, Denora, Nunzio, Stefanachi, Angela, Leonetti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7352889/
https://ncbi.nlm.nih.gov/pubmed/32586039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21124469
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!